An observational study in Atherosclerosis, Coronary and Coronary Stenosis, sponsored by Seung-Jung Park. Recruiting at 8 sites in South Korea. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-01-02.
Sponsored by Seung-Jung Park · Observational
Among 59 studies in Coronary Artery Disease by Seung-Jung Park — 11 open to participants now, 13 under way, none of them phase 3. Coronary Artery Disease · Seung-Jung Park.
Among the 59 studies in Coronary Artery Disease by Seung-Jung Park, this one is the 25th largest by planned enrollment of the 30 observational ones that give a count, is one of 2 that started in 2018, is one of 30 observational ones, reaches primary completion later than 7 of the 12 other live ones, and was the 51st registered.
4,857 studies on the registry are indexed under Coronary Artery Disease; 890 are open to participants now.
Browse Coronary Artery Disease studies →11 of the 59 studies in Coronary Artery Disease by Seung-Jung Park are open now, in 8 countries. Recruiting first, the newest first:
Seung-Jung Park · Sites in Korea, Republic of
Seung-Jung Park · Sites in Hong Kong, India, Japan and 2 more countries
Seung-Jung Park · Sites in Korea, Republic of
Seung-Jung Park · Sites in Korea, Republic of
Seung-Jung Park · Sites in Korea, Republic of
By country, each count listing its studies:
Of the 588 Coronary Artery Disease studies recruiting now, 402 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 38 take children under 18; 47 take healthy volunteers.
This study: 19 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
59 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 2 started in 2018.
This study's planned enrollment of 500 is above the median of 320 across 1,687 observational studies indexed under Coronary Artery Disease.
Median enrollment 500 across the 29 interventional studies, 2,000 across the 30 observational. Of the 46 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Seung-Jung Park is the lead sponsor of 82 studies on the registry; 13 are open to participants now.
3 of the studies in Coronary Artery Disease by Seung-Jung Park that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02792075Seung-Jung ParkPrognosis of Coronary Stenosis Based on Intracoronary Imaging; A Multicenter, Prospective Observational Study | 2026-12 |
| NCT02038660Seung-Jung ParkDrug-Eluting Balloon Registry in Routine Clinical Practice | 2026-12-31 |
| NCT05829889Seung-Jung ParkFractional Flow Reserve Versus Angiography for Treatment-Decision and Evaluation of Significant Left MAIN Coronary Artery Disease | 2027-06 |
Among the 59 studies in Coronary Artery Disease by Seung-Jung Park, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study evaluates the effectiveness and safety rotational atherectomy in routine clinical practice.
Consecutive percutaneous coronary intervention patients receiving rotational atherectomy
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Procedure: Rotational atherectomy
Percutaneous coronary intervention with rotational atherectomy
Target vessel failure (TVF)
Target vessel failure (TVF) composite of death, nonfatal myocardial infarction (MI), or ischemic-driven Target Vessel Revascularization (TVR) at 12 months after the procedure.
Time frame: 1 year
All death
Time frame: 1-,6-, and 12-months, and 3-,5-years
Cardiac death
Time frame: 1-,6-, and 12-months, and 3-,5-years
Myocardial infarction
Time frame: 1-,6-, and 12-months, and 3-,5-years
Composite of death or myocardial infarction
Time frame: 1-,6-, and 12-months, and 3-,5-years
Composite of cardiac death or myocardial infarction
Time frame: 1-,6-, and 12-months, and 3-,5-years
Target-lesion revascularization (TLR)
Time frame: 1-,6-, and 12-months, and 3-,5-years
Target-vessel revascularization (TVR)
Time frame: 1-,6-, and 12-months, and 3-,5-years
Stent thrombosis
according to Academic Research Consortium (ARC) criteria
Time frame: 1-,6-, and 12-months, and 3-,5-years
Stroke
Time frame: 1-,6-, and 12-months, and 3-,5-years
Procedural success
Post-procedural diameter stenosis \< 30% without death, Q-wave myocardial infarction, or urgent revascularization during the index admission
Time frame: 7 days
Not enrolling at this site.
Not enrolling at this site.
Not enrolling at this site.
Not enrolling at this site.
Plan to share: Undecided
No publications or documents are linked to this record.
Started Sep 2018 (actual). Primary completion is estimated for Dec 2029, 135 months after the start.
Of 634 non-industry observational studies under Coronary Artery Disease, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 122. This study's planned 135 months is above that.
Counting every sponsor, half of 759 studies reached it within 40 months; a quarter within 21 and three quarters within 87.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Seung-Jung Park